On February 12, the Constitutional Court ruled that the Fini-Giovanardi law setting out penalties related to the sale and possession of illegal drugs, was improperly approved, and abrogated the law. Since then, Italy has returned to previous regulations that imposed lighter sanctions on cannabis users. Prisoners' rights organisations argued that harsh drug laws have created a booming prison population in a system that is already overcrowded. Since January 2013, Italy's prisons have been under the scrutiny of the European Court of Human Rights.
Khat is as potent as a strong cup of coffee and has no organised crime involvement – yet the government wants to spend £150m on a ban that would create far more severe problems. When the Advisory Council on the Misuse of Drugs, the government's expert advisors, were asked to consider khat, they said that it would be "inappropriate and disproportionate" to ban it. The cross-party home affairs select committee, on which I serve, produced a unanimous report opposing a ban. And yet the home secretary plans to do it anyway.
A new decree that overhauls Italy's drugs laws paves the way for releasing "thousands of convicted smalltime drug dealers from prison". The move follows parliamentary approval of a decree earlier this month that overhauls Italy's drugs laws and reclassifies marijuana as a soft rather than a hard narcotic. The new law also effectively removes jail time as a sentence for smalltime dealers, offering community service and other options in its place. (See also: Council of Europe lauds Italian moves on prison overcrowding)
The United States federal government is considering easing its position on marijuana, reclassifying it as a less dangerous drug in what marijuana advocates say reflects the changing attitudes nationwide. But drug specialists fear the watershed moment for marijuana research could be a slippery slope for addicts. The Food and Drug Administration (FDA) is reviewing marijuana’s classification to consider changing it from a Schedule I drug. (See also: FDA to evaluate marijuana for potential reclassification as less dangerous drug)
The US Food and Drug Administration is reviewing the medical evidence surrounding the safety and effectiveness of marijuana, a process that could lead to the agency downgrading the drug's current status as a Schedule I drug, the most dangerous classification. "FDA conducts for Health and Human Services a scientific and medical analysis of the drug under consideration," FDA Press Officer Jeff Ventura said. "HHS then recommends to DEA that the drug be placed in a given schedule. DEA considers HHS’ analysis, conducts its own assessment, and makes a final scheduling proposal in the form of a proposed rule." (See also: Scheduling in the international drug control system)
The upcoming United Nations General Assembly Special Session on Drugs (UNGASS) in 2016 is an unprecedented opportunity to review and re-direct national drug control policies and the future of the global drug control regime. As diplomats sit down to rethink international and domestic drug policy, they would do well to recall the mandate of the United Nations, not least to ensure security, human rights and development.